Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ...
Postgraduate Institute for Medicine and RME Collaborative.

Applying Evolving Targeted Therapy in Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se...
Annenberg Center for Health Sciences at Eisenhower

PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team

Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival ratesĀ¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati...
University of Cincinnati

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map